Dr. Silvija Jarnjak, PhD, is the CEO and founder of ImmunoCare, with over 20 years of expertise in immunotherapy, oncology, and immunology. She earned her PhD from the University of Oslo, Norway, specializing in the immunotherapy of cancer.
Dr. Jarnjak leads ImmunoCare in providing personalized and advanced immunotherapy treatments. Her dedication to innovative cancer care ensures that every patient receives tailored guidance and support throughout their treatment journey.
Expertise in Clinical Trials
Dr. Jarnjak has a strong background in designing and overseeing Phase I/II/III clinical trials, particularly in oncology and immunology. She ensures the highest standards of participant safety and data integrity throughout the trial process.
Dr. Jarnjak’s role includes analyzing trial data to assess treatment efficacy and collaborating with teams to deliver successful study outcomes. Her clinical trial experience enhances ImmunoCare’s commitment to pioneering advanced cancer therapies.
With extensive experience in business development, Stefan ensures that ImmunoCare’s expansion aligns with its mission to provide personalized and innovative cancer care. His leadership and vision are essential in enhancing the patient experience and strengthening ImmunoCare’s impact in the field of immunotherapy.
Fluent in English, French, and Italian, Audrey leverages her international expertise to develop compelling campaigns and manage social media outreach.
She plays a key role in fostering partnerships and positioning ImmunoCare for market success through her deep understanding of industry trends and opportunities.
